Navigation Links
Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine
Date:11/1/2010

king statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risks Factors and Uncertainties" in Medicago's Annual Information Form filed on March 24, 2010 with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.


'/>"/>
SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. Medicago reports positive Phase I results for its avian flu pandemic vaccine
9. Medicago named in Presidential report on meeting the challenges of pandemic influenza
10. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
11. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading,international pharmaceutical ... 31, 2007., 2007 Full Year Financial Highlights:, - ... in 2006 - Chemical Division,s ... $45.8 million in 2006. ...
... 31 NxStage Medical,Inc. (Nasdaq: NXTM ), ... that Tom Shea has joined the Company as ... 2008. Mr.,Shea will be responsible for all of ... Mr. Shea joins NxStage with more than ...
... MANASQUAN, NJ., March 31 BioSpace, the world,s leading,online ... will host,the Biotech Beach(TM) Career in La Jolla, CA ... at the Hyatt Regency La Jolla from 2 pm-7 ... science professionals from across Southern California will attend,the biotech ...
Cached Biology Technology:Dragon Pharma announces 2007 full year financial results 2Dragon Pharma announces 2007 full year financial results 3Dragon Pharma announces 2007 full year financial results 4Dragon Pharma announces 2007 full year financial results 5Dragon Pharma announces 2007 full year financial results 6Dragon Pharma announces 2007 full year financial results 7NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 2NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 3Bioscience Career Fair in San Diego Expected to Draw Record Jobseeker Attendance 2
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... Ceramic Society (ACerS) today announced that two companies, Corning ... the organization,s 2010 Corporate Technical Achievement Award for their ... Scan Scintillator, respectively. "We somewhat broke with tradition ... very remarkable products and companies," says ACerS President Edwin ...
... is a response that differs from one animal or ... researchers at Tel Aviv University are challenging what we ... helping clinicians better treat victims of terrorism or natural ... student Rony Izhar of Tel Aviv University,s Department of ...
... by researchers at the National Institute of Standards and ... of a powerfulbut trickydiagnostic technique for cell biology. The ... demonstrates that with improved hardware and better signal ... quickly deliver detailed molecular maps of the contents of ...
Cached Biology News:Corning, GE Healthcare to receive Technical Achievement Award from Ceramic Society 2Is anxiety contagious? 2Is anxiety contagious? 3Faster CARS, less damage: NIST chemical microscopy shows potential for cell diagnostics 2
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Mouse C2C12 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... (PI) is a fluorescent nucleic acid dye ... As a nuclear counterstain, propidium iodide ... in color. The fluorescent red color ... fluorochromes such as FITC, Cy2 or AMCA. ...
... parameter assay for mitochondrial membrane potential ... caspases are detected by carboxyfluorescein (FAM)-labelled ... cell-permeable, non-cytotoxic and bind covalently to ... At the same time the mitochondrial ...
Biology Products: